Association between Amylin and Visfatin in patients with Polycystic Ovarian Syndrome In Babylon province.
DOI:
https://doi.org/10.36329/jkcm/2024/v4.i1.14715Keywords:
ELISA, PCOSAbstract
Background: Polycystic ovarian syndrome represent one of the greatest public endocrinopathies diseases categorized by excess androgens that affects early reproductive age. Women with PCOS have hyperandrogenism due to disorder of normal ovarian or adrenal function that lead to the production of excess androgens. In PCOS patients hyperandrogenism caused by impaired folliculogenesis.
Objectives: This study aimed to measure the levels of Amylin, Visfatin, HOMA-IR,HbA1C in serum of Iraqi females who were consuming Polycystic ovarian syndrome .study correlation between the variables mentioned above
Material and methods : The study included approximately 80 women , ages 20 to 38 year, who were split into two groups of 40 women who have Polycystic ovarian syndrome.The second group comprises of 40 women who appearance to be in respectable health and serves as the control group. Women who smoke, have chronic circumstances like high blood pressure, or who usage illicit drugs wereexcluded from both group.Altogether females (patients and controls) have a body mass index that is used to determine their quantity of overweight (BMI)
.Results: A considerable increase in serum level of Amylin , Visfatin
HbA1C and HOMA-IR levels in PCO women than the control group ,p< 0.05.
Conclusion: this study focusing on less frequently known peptides and proteins that might be interrelate with the pathogenesis of PCOS. Beside the role of these proteins in pathogenesis of PCOS and the probability and efficacy of assessing their levels in clinical practice.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Lina Kadhim Thejeel Lina al-shemary

This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.

